2025 EPS consensus $5.18. Raises 2025 revenue view to $1.30B-$1.375B from $1.275B-$1.355B, consensus $1.32B.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61
- Is HALO a Buy, Before Earnings?
- Halozyme price target raised to $65 from $63 at JPMorgan
- Buy Rating for Halozyme: Strong Growth Prospects Backed by Successful MajesTEC-3 Trial and Robust Financial Valuation
- Halozyme price target lowered to $79 from $80 at Morgan Stanley